Workflow
Champions Oncology(CSBR) - 2025 Q1 - Quarterly Results
CSBRChampions Oncology(CSBR)2024-09-11 20:34

Financial Performance - Total revenue for the first quarter of fiscal 2025 was 14.1million,anincreaseof1214.1 million, an increase of 12% compared to 12.6 million in the same period last year[3] - Adjusted EBITDA for the first quarter was 2.0million,asignificantimprovementfromanadjustedEBITDAlossof2.0 million, a significant improvement from an adjusted EBITDA loss of 1.7 million in the first quarter of fiscal 2024[4] - Net income for the first quarter was 1.3million,comparedtoanetlossof1.3 million, compared to a net loss of 2.6 million in the same period last year[4] - Total costs and operating expenses for the first quarter were 12.7million,adecreaseof12.7 million, a decrease of 2.4 million or 15.8% from 15.1millioninthefirstquarteroffiscal2024[3]−Totalmarginimprovedto49.715.1 million in the first quarter of fiscal 2024[3] - Total margin improved to 49.7% for the first quarter, up from 38.8% in the same period last year[5] Cost Management - Cost of oncology services decreased by 612,000, or 8.0%, to 7.1millioncomparedto7.1 million compared to 7.7 million for the same period last year[5] - Research and development expenses decreased by 1.3million,or47.91.3 million, or 47.9%, to 1.5 million compared to 2.8millionforthesameperiodlastyear[6]−Thecompanyplanstocontinuefocusingoncostreductionstomaintainprofitabilitydespitepotentialrevenueandmarginvolatilityinupcomingquarters[2]−Stock−basedcompensationexpensedecreasedto2.8 million for the same period last year[6] - The company plans to continue focusing on cost reductions to maintain profitability despite potential revenue and margin volatility in upcoming quarters[2] - Stock-based compensation expense decreased to 258 from 423year−over−year[16]CashFlowandLiquidity−Thecompanyendedthequarterwithcashonhandofapproximately423 year-over-year[16] Cash Flow and Liquidity - The company ended the quarter with cash on hand of approximately 2.9 million and has no debt[7] - Net cash provided by operating activities was 311,asignificantimprovementfromacashusedof311, a significant improvement from a cash used of 3,991 in the prior year[16] - Cash at the end of the period was 2,892,downfrom2,892, down from 4,869 at the end of the same period last year[16] - Net cash used in investing activities was 668,withnopurchasesofpropertyandequipmentreportedforthecurrentperiod[16]−Netcashusedinfinancingactivitieswas668, with no purchases of property and equipment reported for the current period[16] - Net cash used in financing activities was 37, compared to 590inthepreviousyear[16]−Thecompanyreportedanetincreaseincashof590 in the previous year[16] - The company reported a net increase in cash of 274, contrasting with a decrease of 5,249inthesameperiodlastyear[16]−Changesinoperatingassetsandliabilitiesresultedinacashoutflowof5,249 in the same period last year[16] - Changes in operating assets and liabilities resulted in a cash outflow of 1,927, an improvement from 2,725inthepreviousyear[16]FutureOutlook−Thecompanyiscautiouslyoptimisticaboutfuturegrowth,citingoperationalimprovementsandastrongteamaskeyfactors[2]DepreciationandAllowance−Depreciationandamortizationexpenseremainedrelativelystableat2,725 in the previous year[16] Future Outlook - The company is cautiously optimistic about future growth, citing operational improvements and a strong team as key factors[2] Depreciation and Allowance - Depreciation and amortization expense remained relatively stable at 449, compared to 445intheprioryear[16]−Allowancefordoubtfulaccountsandestimatedcreditlossesshowedareversalof445 in the prior year[16] - Allowance for doubtful accounts and estimated credit losses showed a reversal of 71, compared to an expense of $162 in the previous year[16]